Antipsychotic Drugs

Correct Answer

A — Deutetrabenazine

Rationale

Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor approved specifically for tardive dyskinesia and is administered twice daily. It is a deuterium-substituted derivative of tetrabenazine with a more favorable adverse effect profile than its parent compound. Valbenazine is the other vesicular monoamine transporter 2 inhibitor approved for tardive dyskinesia, but it is administered once daily — the key classification distinction between the two agents. Dantrolene is a direct-acting skeletal muscle relaxant used in neuroleptic malignant syndrome. Bromocriptine is a dopamine agonist used to restore central dopaminergic tone in neuroleptic malignant syndrome.

Correct Answer

C — Cyproheptadine

Rationale

Cyproheptadine is classified as a serotonin antagonist and is used in the pharmacological treatment of serotonin syndrome, where it blocks serotonin receptors to reduce the excess serotonergic activity that drives the syndrome. Dantrolene is a direct-acting skeletal muscle relaxant used in neuroleptic malignant syndrome. Bromocriptine is a dopamine agonist used to restore central dopaminergic tone in neuroleptic malignant syndrome. Benztropine is an anticholinergic used to treat acute dystonia and drug-induced parkinsonism. Recognizing which agent treats which hyperthermia syndrome is a high-yield clinical distinction: neuroleptic malignant syndrome requires dantrolene and bromocriptine; serotonin syndrome requires cyproheptadine and removal of the serotonergic agent.

Correct Answer

B — Amantadine

Rationale

Amantadine is classified as a dopaminergic and glutamatergic agent and serves as an alternative to anticholinergic drugs for the management of antipsychotic-induced drug-induced parkinsonism. It is preferred over anticholinergics such as benztropine in elderly patients because anticholinergic drugs carry a substantial cognitive burden — including impairment of memory, concentration, and attention — that is particularly problematic in patients who already have cognitive vulnerabilities. Benztropine is an anticholinergic that is effective for drug-induced parkinsonism but carries this cognitive risk. Propranolol is a beta-adrenergic blocker that is the first-line treatment for akathisia, not drug-induced parkinsonism. Glycopyrrolate is a peripherally acting anticholinergic used specifically to manage clozapine-induced sialorrhea.

Correct Answer

D — Glycopyrrolate

Rationale

Glycopyrrolate is a peripherally acting anticholinergic that does not cross the blood-brain barrier in clinically meaningful amounts. This pharmacokinetic property makes it useful for managing clozapine-induced sialorrhea — it blocks muscarinic receptors in the salivary glands, reducing secretion, without the central cognitive impairment (confusion, memory difficulty, sedation) that occurs with centrally acting anticholinergics such as atropine, benztropine, and scopolamine. Clozapine-induced sialorrhea is paradoxical — it occurs despite clozapine's muscarinic M1 antagonism because clozapine also acts as an agonist at muscarinic M4 receptors in the salivary glands, stimulating secretion. Atropine and scopolamine are centrally active anticholinergics that would worsen cognitive function in patients already at risk for cognitive impairment. Benztropine is used for extrapyramidal symptoms and also carries central cognitive effects.

Correct Answer

A — Bromocriptine

Rationale

Bromocriptine is classified as a dopamine agonist and is used alongside dantrolene in the pharmacological treatment of neuroleptic malignant syndrome. Because neuroleptic malignant syndrome results from sudden, severe dopamine blockade, bromocriptine restores central dopaminergic tone and may accelerate recovery. Cyproheptadine is a serotonin antagonist used specifically for serotonin syndrome. Glycopyrrolate is a peripheral anticholinergic used to manage clozapine-induced sialorrhea. Amantadine also has dopaminergic activity and is sometimes used in neuroleptic malignant syndrome management, but is classified primarily as a dopaminergic agent for drug-induced parkinsonism rather than specifically as a treatment for neuroleptic malignant syndrome.

Correct Answer

C — Granulocyte colony-stimulating factor

Rationale

Granulocyte colony-stimulating factor is a growth factor that stimulates the bone marrow to produce and release neutrophils. In severe cases of clozapine-induced agranulocytosis — where the absolute neutrophil count falls to dangerously low levels — it can be used adjunctively to accelerate neutrophil recovery alongside clozapine discontinuation and supportive care. It does not replace the mandatory Risk Evaluation and Mitigation Strategy monitoring protocol, which exists to catch the absolute neutrophil count drop before agranulocytosis becomes life-threatening. Valbenazine is a vesicular monoamine transporter 2 inhibitor for tardive dyskinesia. Metformin is a pharmacological adjunct for antipsychotic-induced weight gain. Dantrolene is a muscle relaxant used in neuroleptic malignant syndrome.

Correct Answer

D — Neuroleptic malignant syndrome produces lead-pipe rigidity with bradyreflexia; serotonin syndrome produces hyperreflexia and clonus

Rationale

The neuromuscular examination is the most reliable bedside tool for distinguishing neuroleptic malignant syndrome from serotonin syndrome. Neuroleptic malignant syndrome produces severe generalized lead-pipe rigidity — uniform resistance throughout the range of motion — accompanied by bradyreflexia (reduced or absent deep tendon reflexes). This pattern reflects the loss of central dopaminergic tone caused by antipsychotic D2 blockade. Serotonin syndrome produces the opposite pattern: hyperreflexia (exaggerated deep tendon reflexes) and clonus (rhythmic involuntary muscle contractions elicited by sustained passive stretch), reflecting hyperactivation of serotonin-mediated spinal motor circuits by excess serotonin. The onset timing also differs: neuroleptic malignant syndrome develops slowly over 24 to 72 hours, while serotonin syndrome typically develops within hours of a serotonergic medication change. This distinction matters because treatment differs — neuroleptic malignant syndrome requires dantrolene and bromocriptine; serotonin syndrome requires removal of the serotonergic agent and cyproheptadine.

Correct Answer

B — They inhibit the vesicular monoamine transporter 2, depleting presynaptic dopamine stores and reducing the amount of dopamine available to activate the supersensitive striatal D2 receptors

Rationale

The vesicular monoamine transporter 2 is the transporter responsible for packaging dopamine into synaptic vesicles before release. By inhibiting this transporter, valbenazine and deutetrabenazine prevent dopamine from being loaded into vesicles for exocytotic release, progressively depleting presynaptic dopamine stores. With less dopamine available in the synapse, the supersensitive D2 receptors in the striatum — which developed as a compensatory response to chronic antipsychotic blockade — are less frequently activated, reducing the hyperkinetic involuntary movements of tardive dyskinesia. This mechanism operates presynaptically, which is why these drugs can treat tardive dyskinesia without requiring the antipsychotic to be discontinued: the vesicular monoamine transporter 2 inhibitor reduces dopamine release while the antipsychotic continues to block remaining D2 receptors, achieving a pharmacological balance that controls movements without precipitating psychotic relapse.

Correct Answer

C — A 68-year-old female who has been on haloperidol for 8 years for chronic schizophrenia

Rationale

Tardive dyskinesia risk is determined by a combination of patient and treatment factors. This patient accumulates the highest risk profile: older age (68 years — elderly patients have substantially elevated risk), female sex, a high-potency first-generation antipsychotic (haloperidol carries the highest tardive dyskinesia liability of any commonly used agent), and 8 years of continuous exposure. The annual incidence of tardive dyskinesia with first-generation antipsychotics is approximately 5 percent per year for the first several years, with cumulative risk approaching 20 to 30 percent after 5 years. Quetiapine carries minimal tardive dyskinesia risk due to its fast D2 dissociation kinetics. Aripiprazole, a partial D2 agonist, carries low tardive dyskinesia risk due to nigrostriatal dopamine stabilization rather than depletion. Risperidone carries low but nonzero tardive dyskinesia risk as a second-generation antipsychotic, approximately 0.5 to 1 percent per year.

Correct Answer

A — Rechallenge with clozapine is permanently prohibited; granulocyte colony-stimulating factor may be used adjunctively to stimulate neutrophil recovery

Rationale

When a patient's absolute neutrophil count falls below 500 cells per microliter on clozapine — meeting the definition of agranulocytosis — permanent discontinuation of clozapine is required and rechallenge is not permitted under any circumstances. The idiosyncratic mechanism that caused bone marrow toxicity in this patient is likely to recur upon re-exposure, and a second episode of agranulocytosis could be fatal. There is no waiting period or dose reduction strategy that makes rechallenge acceptable. For the acute episode, granulocyte colony-stimulating factor is a pharmacological adjunct that stimulates the bone marrow to produce and release neutrophils, potentially accelerating recovery. This does not change the rechallenge prohibition — the goal is to manage the current episode safely while permanently avoiding further clozapine exposure. If the absolute neutrophil count falls between 500 and 1000 cells per microliter (severe neutropenia rather than agranulocytosis), clozapine must be interrupted and a decision about permanent discontinuation is made based on clinical context, with careful monitoring during any rechallenge attempt.

Correct Answer

D — Hypokalemia and hypomagnesemia independently lower the threshold for torsades de pointes, compounding the QTc prolongation risk from ziprasidone

Rationale

Ziprasidone produces mean QTc prolongation of approximately 10 milliseconds at standard doses by blocking the cardiac repolarization current. Hypokalemia and hypomagnesemia are independent risk factors for torsades de pointes because both electrolytes are required for normal cardiac repolarization. Low potassium reduces the inward rectifier potassium current that contributes to stable resting membrane potential; low magnesium impairs the sodium-potassium ATPase and directly destabilizes cardiac conduction. Both deficits individually lower the threshold at which QTc prolongation triggers the polymorphic ventricular tachycardia of torsades de pointes. When these electrolyte abnormalities are present alongside a QTc-prolonging antipsychotic, the combined cardiac risk is substantially greater than either factor alone. Correction of hypokalemia and hypomagnesemia before initiating or continuing QTc-active antipsychotics is mandatory and is one of the most important — and frequently overlooked — interventions in antipsychotic safety management.

Correct Answer

B — Aripiprazole's partial D2 agonism in the tuberoinfundibular pathway competes with risperidone for receptor occupancy, partially restoring dopaminergic inhibition of prolactin secretion

Rationale

Risperidone is a full D2 antagonist that blocks tuberoinfundibular D2 receptors completely, removing the dopaminergic inhibition of prolactin secretion and causing hyperprolactinemia. Aripiprazole is a partial D2 agonist — at low doses, it competes with risperidone for tuberoinfundibular D2 receptor occupancy. Because aripiprazole activates these receptors to a partial degree rather than blocking them completely, it partially restores the dopaminergic inhibitory signal that suppresses prolactin. The result is a meaningful reduction in prolactin levels without requiring the risperidone to be discontinued. Several randomized trials support this strategy specifically for risperidone- and paliperidone-induced hyperprolactinemia — the agents with the highest prolactin-elevating liability in the second-generation class. Low doses of aripiprazole (5 to 15 milligrams per day) are typically sufficient because the goal is partial tuberoinfundibular D2 activation, not full antipsychotic effect.

Correct Answer

C — Dantrolene inhibits calcium release from the sarcoplasmic reticulum in skeletal muscle, reducing rigidity and heat production; bromocriptine is a dopamine agonist that restores the central dopaminergic tone lost from antipsychotic blockade

Rationale

Dantrolene acts as a direct-acting skeletal muscle relaxant by inhibiting calcium release from the sarcoplasmic reticulum inside muscle fibers. Without calcium, the muscle contraction cycle cannot proceed, and the severe generalized lead-pipe rigidity of neuroleptic malignant syndrome is reduced. Because rigidity generates substantial heat through sustained muscular work, reducing it also lowers the hyperthermia. Bromocriptine addresses the underlying pharmacological cause: neuroleptic malignant syndrome results from abrupt, severe loss of central dopaminergic tone due to antipsychotic D2 blockade. Bromocriptine, a dopamine agonist, directly activates central dopamine receptors and partially restores the dopaminergic signaling that the antipsychotic has eliminated. Together, these drugs address the two primary pathophysiological drivers of neuroleptic malignant syndrome: the peripheral rigidity and the central dopamine deficiency. This combination is used alongside stopping the offending antipsychotic, aggressive cooling, and intensive care unit supportive care.

Correct Answer

A — Contraindicated in untreated depression or active suicidality; the primary advantage is that tardive dyskinesia can be treated without requiring the antipsychotic to be discontinued

Rationale

Vesicular monoamine transporter 2 inhibitors deplete presynaptic stores of dopamine, serotonin, and norepinephrine. The depletion of serotonin and norepinephrine creates a risk of worsening depression and suicidality, making these agents contraindicated in patients with untreated depression or active suicidality — a clinically important consideration because depression co-occurs commonly in patients with schizophrenia and tardive dyskinesia. Both valbenazine and deutetrabenazine carry somnolence as a class adverse effect. The primary clinical advantage is that these agents allow tardive dyskinesia to be treated while maintaining the antipsychotic that is controlling the patient's psychosis — resolving the otherwise difficult dilemma of choosing between psychiatric stability and movement disorder management. Vesicular monoamine transporter 2 inhibitors suppress rather than cure tardive dyskinesia; movements typically return if the drug is discontinued, and complete resolution of tardive dyskinesia is uncommon even with prolonged treatment.

Correct Answer

C — Haloperidol's potent dopamine D2 blockade causes abrupt loss of central dopaminergic tone, producing the neuroleptic malignant syndrome tetrad of hyperthermia, lead-pipe rigidity, autonomic instability, and altered consciousness

Rationale

This patient has neuroleptic malignant syndrome — a rare but potentially fatal idiosyncratic reaction to antipsychotic medications. The tetrad of hyperthermia, severe lead-pipe muscle rigidity, autonomic instability, and altered consciousness developed over several days in a patient on haloperidol, a high-potency first-generation antipsychotic. The markedly elevated creatine kinase reflects rhabdomyolysis caused by the intense sustained muscle rigidity. The mechanism is loss of central dopaminergic tone: dopamine plays a critical role in hypothalamic temperature regulation and in coordinating motor and autonomic function. Abrupt, profound D2 blockade by haloperidol disrupts these dopaminergic circuits simultaneously, producing the full syndrome. Management requires immediate haloperidol discontinuation, aggressive cooling, vigorous fluid resuscitation to protect renal function from myoglobin, and intensive care unit admission. Dantrolene reduces rigidity by inhibiting sarcoplasmic reticulum calcium release; bromocriptine restores central dopaminergic tone. A minimum 2-week wait after full clinical recovery is required before restarting any antipsychotic.

Correct Answer

B — Aripiprazole's partial D2 agonism in the tuberoinfundibular pathway partially restores dopaminergic inhibition of prolactin secretion from pituitary lactotroph cells

Rationale

Risperidone is a full D2 antagonist that completely blocks tuberoinfundibular D2 receptors, removing the dopaminergic inhibition that normally suppresses prolactin release from pituitary lactotroph cells. Aripiprazole is a partial D2 agonist — when added at low doses, it competes with risperidone for tuberoinfundibular D2 receptor occupancy. Because aripiprazole activates these receptors to a partial degree rather than blocking them completely, it partially restores the dopaminergic inhibitory signal on prolactin secretion. The net effect is a meaningful reduction in serum prolactin and clinical resolution of hyperprolactinemia symptoms, without requiring risperidone discontinuation. This strategy is supported by randomized trial evidence specifically for risperidone- and paliperidone-induced hyperprolactinemia. The dose of aripiprazole needed for this effect (5 to 15 milligrams per day) is lower than a full antipsychotic dose, reflecting the goal of partial tuberoinfundibular D2 activation rather than mesolimbic antipsychotic efficacy.

Correct Answer

D — Valbenazine — vesicular monoamine transporter 2 inhibition depletes presynaptic dopamine, reducing activation of the supersensitive striatal D2 receptors that drive involuntary movements

Rationale

Valbenazine is a vesicular monoamine transporter 2 inhibitor with Food and Drug Administration approval specifically for tardive dyskinesia and can be added to the patient's existing antipsychotic regimen without requiring fluphenazine to be discontinued. By inhibiting the vesicular monoamine transporter 2, valbenazine depletes presynaptic dopamine stores and reduces the dopamine available to activate the supersensitive striatal D2 receptors that developed in response to chronic antipsychotic blockade — suppressing the involuntary movements. This is the defining pharmacological advantage of vesicular monoamine transporter 2 inhibitors for tardive dyskinesia: they address the movement disorder at the presynaptic level without interfering with the postsynaptic D2 blockade that controls the patient's psychosis. Benztropine treats acute dystonia and drug-induced parkinsonism, not tardive dyskinesia. Propranolol treats akathisia. Aripiprazole's partial agonism may provide some incidental benefit in tardive dyskinesia but does not have regulatory approval for this indication.

Correct Answer

A — This is serotonin syndrome — excess serotonergic activity hyperactivates spinal motor circuits, producing hyperreflexia and clonus with rapid onset; neuroleptic malignant syndrome produces lead-pipe rigidity with bradyreflexia and slower onset from dopamine blockade

Rationale

This patient has serotonin syndrome, caused by a pharmacodynamic interaction between fluoxetine (a selective serotonin reuptake inhibitor that increases synaptic serotonin) and tramadol (which has serotonin reuptake inhibitor activity in addition to its opioid mechanism). The combination of these agents produces excessive serotonergic activity, which hyperactivates serotonin receptors in the spinal cord that normally regulate motor neuron excitability — producing the characteristic hyperreflexia and clonus. The rapid onset (within hours of starting tramadol) and the specific neuromuscular findings — hyperreflexia and clonus rather than uniform rigidity — are the key features that distinguish serotonin syndrome from neuroleptic malignant syndrome. Neuroleptic malignant syndrome produces lead-pipe rigidity with bradyreflexia and develops slowly over 24 to 72 hours in patients on antipsychotic medications. Treatment of serotonin syndrome requires stopping all serotonergic agents and administering cyproheptadine, a serotonin antagonist — not dantrolene or bromocriptine, which are used for neuroleptic malignant syndrome.